TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms (1), and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia (2). Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.1) Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIPL1-PDGFRA correlates. Leukemia 2009; 23:900-4.
Immunogen
TET2 antibody was raised against an 18 amino acid peptide near the carboxy terminus of human TET2. The immunogen is located within amino acids 1550 - 1600 of TET2.
Key Feature
Clonality
Polyclonal
Isotype
IgG
Host Species
Rabbit
Tested Applications
ELISAWB
TET2 antibody can be used for detection of TET2 by Western blot at 1 - 2 μg/ml.:
TET2 antibody is human and mouse reactive. At least two isoforms of TET2 are known to exist; this antibody will detect the larger isoforms. This antibody is predicted to not cross-react with TET1 and TET3.